Use of human cord blood-derived pluripotent cells for the treatment of disease

• US 20090181087A1
• Filed: 12/20/2004
• Published: 07/16/2009
• Est. Priority Date: 12/19/2003
• Status: Abandoned Application

• Current Assignee: ViaCord LLC (Revvity, Inc.)
• Original Assignee: Viacell Incorporated (Revvity, Inc.)
• Inventors: Kraus, Morey, Beer, Marc D., Clark, Paul T.
• Application Number:
  US10/583,684
• Publication Number:
  US 20090181087A1
• Time in Patent Office: Days
• US Class Current: 424/484
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 35/407 Liver; Hepatocytes
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: C12N 5/0665 Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: G01N 33/5094 for blood cell populations red blood cells G01N33/80

Abstract

The present invention features methods of organ tissue regeneration using pluripotent cells derived from umbilical cord blood, compositions of these pluripotent cells, methods for further transforming these cells, and uses for these transformed cells.

Claims

1. A method of treating a vascular, muscle, hepatic, pancreatic, or neural disease, said method comprising the step of administering to a patient a pluripotent cell or a progeny cell derived therefrom prepared from human umbilical cord blood, placental blood, or a blood sample from a newborn human, wherein said pluripotent cell

(a) expresses SH2, SH3, SH4, CD13, CD29, CD49e, CD54, and CD90 antigen markers;

(b) does not express CD14, CD31, CD34, CD45, CD49d, or CD106 antigen markers; and

(c) is capable of differentiating into one or more of a mesenchymal pluripotent cell, a hematopoietic pluripotent cell, a neural pluripotent cell, or an endothelial pluripotent cell.

2. The method of claim 1, wherein said disease is a vascular disease.

3. The method of claim 1, wherein said disease is a smooth muscle or cardiac muscle disease.

4. The method of claim 1, wherein said disease is a hepatic disease.

5. The method of claim 1, wherein said disease is a pancreatic disease.

6. The method of claim 1, wherein said disease is a neural disease.

7. The method of claim 1, wherein said method comprises administering said cell to effect organ regeneration.

8. The method of claim 1, wherein multiple said cells are used to grow a blood vessel in vitro, which is implanted in said patient.

9. The method of claim 1, wherein said progeny cell of said pluripotent cell is administered to said patient.

10. The method of claim 9, further comprising inducing said progeny cell to express an endothelial cell marker before administering said progeny cell to said patient.

11. The method of claim 9, wherein said progeny cell expresses a marker recognized by a P1H12 monoclonal antibody.

12. The method of claim 9, further comprising inducing said progeny cell to express a liver cell marker before administering said progeny cell to said patient.

13. The method of claim 9, further comprising inducing said progeny cell to express a pancreatic cell marker before administering said progeny cell to said patient.

14. The method of claim 9, further comprising inducing said progeny cell to express a nerve cell marker before administering said progeny cell to said patient.

15. The method of claim 9, further comprising inducing said progeny cell to express a cardiac or smooth muscle cell marker before administering said progeny cell to said patient.

16. A method of whether a test agent induces differentiation of an isolated pluripotent cell, said method comprising contacting said pluripotent cell characterized by the expression of SH2, SH3, SH4, CD 13, CD29, CD49e, CD54, and CD90 antigens, and lacking the expression of CD14, CD34, CD45, CD49d, and CD106 antigens with said test agent and detecting a change in marker expression of said contacted pluripotent cell, wherein said change indicates that said test agent induces differentiation of said isolated pluripotent cell.

17. A method for producing a population of cells characterized by the expression of SH2, SH3, SH4, CD13, CD29, CD49e, CD54, and CD90 antigen markers, and lacking the expression of CD14, CD34, CD45, CD49d, and CD106 antigen markers, said method comprising the steps of:

a. providing pluripotent cells derived from umbilical cord blood and capable of differentiating into mesenchymal pluripotent cells, hematopoietic pluripotent cells, neural pluripotent cells, or endothelial pluripotent cells;

b. culturing said pluripotent cells in a medium containing dexamethasone for a time sufficient to expand said population of pluripotent cells; and

c. isolating said pluripotent cells from said culture, wherein greater than 20% of said isolated pluripotent cells are positive for SH2, SH3, SH4, CD13, CD29, CD49e, CD54, and CD90 markers, and negative for CD14, CD34, CD45, CD49d, and CD106 markers.

18. A composition comprising multiple pluripotent cells that are positive for SH2, SH3, SH4, CD13, CD29, CD49e, CD54, and CD90 markers, and negative for CD14, CD34, CD45, CD49d, and CD106 markers, suspended a pharmaceutically acceptable carrier.

33. The composition of claim 18, wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, a gel, a hydrogel, a sponge, and a matrix.

19-32. -32. (canceled)

34. A pluripotent progeny cell obtained by the in vitro or ex vivo transfection with DNA encoding a desired protein of a pluripotent cell positive for SH2, SH3, SH4, CD13, CD29, CD49e, CD54, and CD90 markers, and negative for CD14, CD34, CD45, CD49d, and CD106 markers.

35. A composition comprising multiple cells of claim 34, suspended in a pharmaceutically acceptable carrier.

36. The composition of claim 34, wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, a gel, a hydrogel, a sponge, and a matrix.

37. A therapeutic method comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 35.

38. The method of claim 36, wherein said cells express in said patient a therapeutically effective amount of said desired protein.

39. The method of claim 34, wherein said pluripotent cell is capable of differentiating into all of the same cell types as said pluripotent cells.

40. Use in the preparation of a medicament for the treatment of a vascular, hepatic, pancreatic or neural disease, of a pluripotent cell or progeny thereof prepared from umbilical cord blood, placental blood, or blood prepared from a newborn human, wherein said pluripotent cell a) is positive for SH2, SH3, SH4, CD13, CD29, CD49e, CD54, and CD90 markers, b) is negative for CD14, CD34, CD45, CD49d, and CD106 markers, and c) is capable of differentiating into one or more of a mesenchymal pluripotent cell, a hematopoietic pluripotent cell, a neural pluripotent cell, or an endothelial pluripotent cell.

41. The use of claim 40, wherein said disease is a vascular disease.

42. The use of claim 40, wherein said disease is a smooth muscle or cardiac muscle disease.

43. The use of claim 40, wherein said disease is a hepatic disease.

44. The use of claim 40, wherein said disease is a pancreatic disease.

45. The use of claim 40, wherein said disease is a neural disease.

46. The use of claim 40, wherein the cells are used for organic regeneration.

47. The use of claim 40, wherein said cell is a said progeny cell that expresses the endothelial cell marker P1H12.